Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A novel molecular staging protocol for non-small cell lung cancer

Oncogene volume 18, pages 2397–2404 (1999)Cite this article

Abstract

A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA were extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5 – 8, and mutations of K-ras at exon 1. To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT – PCR. A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were significant factors for prognosis (P<0.0001, P=0.0083 and P=0.0004, respectively). Based on these results, we classified the patients into three groups according to their MRP-1/CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild K-ras tumors were defined as group A, patients with either reduced MRP-1/CD9 or mutant K-ras tumors were defined as group B and patients with both reduced MRP-1/CD9 and mutant K-ras tumors were designated as group C. This new classification was significantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was significantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients was better than the group C patients (27.9% vs 20.0%, P=0.0378). This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9% vs 0.0%, P<0.0001). A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a significant prognostic effect as well as nodal status (P<0.0001).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Adachi M, Taki T, Ieki Y, Huang C, Higashiyama M and Miyake M. . 1996 Cancer Res. 56: 1751–1755.

  • Bains MS. . 1991 Chest 100: 826–837.

  • Cajot J, Sordat I, Silvestre T and Sordat B. . 1997 Cancer Res. 57: 2593–2597.

  • Chomczynski P and Sacchi N. . 1987 Anal Biochem. 162: 156–159.

  • Cox DR. . 1972 JR. Stat. Soc. B. 34: 187–220.

  • Curiel DT, Pilewski JM and Albelda SM. . 1996 Am. J. Respir. Cell. Mol. Biol. 14: 1–18.

  • Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT and Barrett JC. . 1995 Science 268: 884–886.

  • Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K and Sugimachi K. . 1997 Br. J. Cancer 75: 1125–1130.

  • Greenblatt MS, Bennett WP, Hollstein M and Harris CC. . 1994 Cancer Res. 54: 4855–4878.

  • Higashiyama M, Taki T, Ieki Y, Adachi M, Huang C, Koh T, Kodama K, Doi O and Miyake M. . 1995 Cancer Res. 55: 6040–6044.

  • Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF and Rice JM. . 1995 Cancer Res. 55: 2665–2672.

  • Huang C, Taki T, Adachi M, Yagita M, Sawada S, Takabayshi A, Inufusa H, Yoshie O and Miyake M. . 1997 Int. J. Oncol. 11: 1045–1051.

  • Huang C, Taki T, Adachi M, Konishi T, Higashiyama M and Miyake M. . 1998 Oncogene 16: 2469–2477.

  • Ikeyama S, Koyama M, Yamaoka M, Sasada R and Miyake M. . 1993 J. Exp. Med. 177: 1231–1237.

  • Kaplan EL and Meier P. . 1958 J. Am. Stat. Assoc. 53: 457–481.

  • Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN and Hong WK. . 1995 J. Clin. Oncol. 13: 1893–1903.

  • Mantel N. . 1966 Cancer Chemother. Rep. 50: 163–170.

  • Masters GA, Vokes EE and Golomb HM. . 1996 Adv. Oncol. 12: 16–21.

  • Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T. . 1993 J. Natl. Cancer Inst. 85: 2018–2023.

  • Miyake M, Koyama M, Seno M and Ikeyama S. . 1991 J. Exp. Med. 174: 1347–1354.

  • Miyake M, Taki T, Hitomi S and Hakomori S. . 1992 N. Engl. J. Med. 327: 14–18.

  • Miyake M, Nakano K, Itoi S, Koh T and Taki T. . 1996 Cancer Res. 56: 1244–1249.

  • Mountain CF. . 1997 Chest 111: 1710–1717.

  • Nakajima-Iijima S, Hamada H, Reddy P and Kakunaga T. . 1985 Proc. Natl. Acad. Sci. USA 82: 6133–6137.

  • Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A and Ariza A. . 1993 Oncogene 8: 2407–2412.

  • Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T and Cai D. . 1996 Nat. Med. 2: 985–991.

  • Sambrook J, Fitsch EF and Maniatis T. . (1989) (eds). Molecular cloning. In A Laboratory Manual, Vol 3 Cold Spring Harbor Laboratory Press, New York. pp E.3–E.4.

    Google Scholar 

  • Sklar MD. . 1988 Science 239: 645–647.

  • Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SS, Wanderschueren RGJRA, Zandwijk NV, Mooi WJ, Bos JL and Rodenhuis S. . 1990 N. Engl. J. Med. 323: 561–565.

  • Sundaresan V, Heppell-Parton A, Coleman N, Miozzo M, Sozzi G, Ball R, Cary N, Hasleton P, Fowler W and Rabbitts P. . 1995 Ann. Oncol. 6: S27–S32.

  • Takahashi K and Sawasaki Y. . 1992 In Vitro Cell Dev. Biol. 28A: 380–382.

  • Zhang Y, Mukhopadhyay T, Donehower LA, Gerorges RM and Roth JA. . 1993 Hum. Gene Ther. 4: 451–460.

Download references

Acknowledgements

We thank Dr Masato Yagita for his critical editorial help with the manuscript. Supported in part by Grants-in-Aid from the Ministry of Education, Science and Culture of Japan to MM (No 07557253 and 08407040).

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery and Department V of Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute, 530, Osaka, Japan

    Masayuki Miyake, Masashi Adachi, Cheng-long Huang & Toshihiko Taki

  2. Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 537, Osaka, Japan

    Masahiko Higashiyama & Ken Kodama

Authors
  1. Masayuki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masashi Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng-long Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiko Higashiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken Kodama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshihiko Taki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyake, M., Adachi, M., Huang, Cl. et al. A novel molecular staging protocol for non-small cell lung cancer. Oncogene 18, 2397–2404 (1999). https://doi.org/10.1038/sj.onc.1202556

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202556

Keywords

This article is cited by

Search

Advanced search

Quick links